| Quarter | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| 23 | 38 | 52 | 134 | 101 | 108 | |
Growth YoY Revenue Growth YoY% | 471.1 | 187.7 | ||||
| 19 | 34 | 49 | 124 | 89 | 91 | |
| 4 | 4 | 4 | 10 | 12 | 17 | |
OPM OPM% | 17.8 | 10.3 | 6.8 | 7.6 | 12.1 | 16.0 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 1 | 1 | 1 |
PBT PBTCr | 4 | 3 | 3 | 8 | 10 | 15 |
| 1 | 1 | 1 | 1 | 1 | 6 | |
| 3 | 3 | 2 | 8 | 9 | 10 | |
Growth YoY PAT Growth YoY% | 180.3 | 278.7 | ||||
NPM NPM% | 11.7 | 6.9 | 4.5 | 5.7 | 9.3 | 9.1 |
| 2.8 | 2.4 | 2.2 | 2.0 | 2.2 | 2.2 |
| Quarter | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| 23 | 38 | 52 | 134 | 101 | 108 | |
Growth YoY Revenue Growth YoY% | 471.1 | 187.7 | ||||
| 19 | 34 | 49 | 124 | 89 | 91 | |
| 4 | 4 | 4 | 10 | 12 | 17 | |
OPM OPM% | 17.8 | 10.3 | 6.8 | 7.6 | 12.1 | 16.0 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 1 | 1 | 1 |
PBT PBTCr | 4 | 3 | 3 | 8 | 10 | 15 |
| 1 | 1 | 1 | 1 | 1 | 6 | |
| 3 | 3 | 2 | 8 | 9 | 10 | |
Growth YoY PAT Growth YoY% | 180.3 | 278.7 | ||||
NPM NPM% | 11.7 | 6.9 | 4.5 | 5.7 | 9.3 | 9.1 |
| 2.8 | 2.4 | 2.2 | 2.0 | 2.2 | 2.2 |
| Financial Year | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
Revenue RevenueCr | 64 | 250 | 395 |
Growth Revenue Growth% | 289.4 | ||
| 51 | 229 | 352 | |
| 13 | 21 | 43 | |
OPM OPM% | 19.9 | 8.3 | 10.9 |
| 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 1 | 2 | 4 |
Depreciation DepreciationCr | 0 | 1 | 3 |
PBT PBTCr | 12 | 18 | 37 |
| 3 | 3 | 8 | |
PAT PATCr | 9 | 15 | 29 |
Growth PAT Growth% | 64.8 | ||
NPM NPM% | 13.9 | 5.9 | 7.4 |
| 9.1 | 4.8 | 8.7 |
| Financial Year | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
Revenue RevenueCr | 64 | 250 | 395 |
Growth Revenue Growth% | 289.4 | ||
| 51 | 229 | 352 | |
| 13 | 21 | 43 | |
OPM OPM% | 19.9 | 8.3 | 10.9 |
| 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 1 | 2 | 4 |
Depreciation DepreciationCr | 0 | 1 | 3 |
PBT PBTCr | 12 | 18 | 37 |
| 3 | 3 | 8 | |
PAT PATCr | 9 | 15 | 29 |
Growth PAT Growth% | 64.8 | ||
NPM NPM% | 13.9 | 5.9 | 7.4 |
| 9.1 | 4.8 | 8.7 |
| Financial Year | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 10 | 42 | 44 |
Reserves ReservesCr | 22 | 289 | 314 |
| 27 | 165 | 169 | |
| 1 | 20 | 21 | |
| 63 | 519 | 547 | |
| 46 | 243 | 273 | |
| 18 | 276 | 274 | |
| 63 | 519 | 547 |
| Financial Year | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 10 | 42 | 44 |
Reserves ReservesCr | 22 | 289 | 314 |
| 27 | 165 | 169 | |
| 1 | 20 | 21 | |
| 63 | 519 | 547 | |
| 46 | 243 | 273 | |
| 18 | 276 | 274 | |
| 63 | 519 | 547 |
| Financial Year | Mar 2025 | Mar 2026 |
|---|---|---|
| -13 | -18 | |
| -8 | -2 | |
| 3 | 3 | |
Net Cash Flow Net Cash FlowCr | -17 | -17 |
Free Cash Flow Free Cash FlowCr | -18 | -19 |
CFO To PAT CFO To PAT% | -140.3 | -120.3 |
CFO To EBITDA CFO To EBITDA% | -98.0 | -85.2 |
| Financial Year | Mar 2025 | Mar 2026 |
|---|---|---|
| -13 | -18 | |
| -8 | -2 | |
| 3 | 3 | |
Net Cash Flow Net Cash FlowCr | -17 | -17 |
Free Cash Flow Free Cash FlowCr | -18 | -19 |
CFO To PAT CFO To PAT% | -140.3 | -120.3 |
CFO To EBITDA CFO To EBITDA% | -98.0 | -85.2 |
| Financial Year | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|
Market Cap Market CapitalizationCr | 75 | 276 | 257 |
Price To Earnings Price To Earnings | 8.4 | 18.8 | 6.8 |
Price To Sales Price To Sales | 1.2 | 1.1 | 0.7 |
Price To Book Price To Book | 2.3 | 0.8 | 0.7 |
EV To EBITDA EV To EBITDA | 6.8 | 15.6 | 7.2 |
GPM GPM% | 24.3 | 11.4 | 11.4 |
OPM OPM% | 19.9 | 8.3 | 10.9 |
NPM NPM% | 13.9 | 5.9 | 7.4 |
ROCE ROCE% | 27.8 | 5.2 | 10.0 |
ROE ROE% | 27.7 | 4.4 | 8.2 |
ROA ROA% | 14.1 | 2.8 | 5.3 |
| Financial Year | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|
Market Cap Market CapitalizationCr | 75 | 276 | 257 |
Price To Earnings Price To Earnings | 8.4 | 18.8 | 6.8 |
Price To Sales Price To Sales | 1.2 | 1.1 | 0.7 |
Price To Book Price To Book | 2.3 | 0.8 | 0.7 |
EV To EBITDA EV To EBITDA | 6.8 | 15.6 | 7.2 |
GPM GPM% | 24.3 | 11.4 | 11.4 |
OPM OPM% | 19.9 | 8.3 | 10.9 |
NPM NPM% | 13.9 | 5.9 | 7.4 |
ROCE ROCE% | 27.8 | 5.2 | 10.0 |
ROE ROE% | 27.7 | 4.4 | 8.2 |
ROA ROA% | 14.1 | 2.8 | 5.3 |
| Market CapitalizationMkt CapCr | 627 | 515 | 487 | 257 | 191 | 163 | 44 |
| Close PriceClose₹ | 179.37 | 94.91 | 1,610.80 | 58.67 | 9.81 | 30.46 | 27.55 |
| IndustryIndustry | Pharma API | Pharma API | Pharma API | Pharma API | Pharma API | Pharma API | Pharma API |
| Price To EarningsPE | 11.13 | 31.74 | 37.59 | 6.78 | 21.60 | ||
| Price To SalesPS | 0.93 | 1.37 | 1.46 | 0.65 | 109.52 | 0.28 | 0.17 |
| RevenueRevenueCr | 676 | 377 | 334 | 395 | 2 | 583 | 262 |
| Revenue Growth TTMRev Gr TTM% | 7.5% | 102.4% | -1.0% | -70.8% | 42.4% | -2.3% | |
| PAT Growth TTMPAT Gr TTM% | 4.8% | 219.7% | -44.7% | 81.7% | 35.8% | -92.5% |
| Market CapitalizationMkt CapCr | 627 | 515 | 487 | 257 | 191 | 163 | 44 |
| Close PriceClose₹ | 179.37 | 94.91 | 1,610.80 | 58.67 | 9.81 | 30.46 | 27.55 |
| IndustryIndustry | Pharma API | Pharma API | Pharma API | Pharma API | Pharma API | Pharma API | Pharma API |
| Price To EarningsPE | 11.13 | 31.74 | 37.59 | 6.78 | 21.60 | ||
| Price To SalesPS | 0.93 | 1.37 | 1.46 | 0.65 | 109.52 | 0.28 | 0.17 |
| RevenueRevenueCr | 676 | 377 | 334 | 395 | 2 | 583 | 262 |
| Revenue Growth TTMRev Gr TTM% | 7.5% | 102.4% | -1.0% | -70.8% | 42.4% | -2.3% | |
| PAT Growth TTMPAT Gr TTM% | 4.8% | 219.7% | -44.7% | 81.7% | 35.8% | -92.5% |